Detalhe da pesquisa
1.
PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Hyperglycemic Mice Increases the Risk of Hemorrhagic Transformation of Ischemic Stroke.
Stroke;
52(9): e545-e547, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34315254
2.
CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.
Immunology;
158(2): 85-93, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31335975
3.
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Arterioscler Thromb Vasc Biol;
38(3): 592-598, 2018 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29284604
4.
Key aspects of PCSK9 inhibition beyond LDL lowering.
Curr Opin Lipidol;
29(6): 453-458, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30199407
5.
Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.
J Lipid Res;
59(5): 892-900, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29540575
6.
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
Clin Sci (Lond);
132(10): 1075-1083, 2018 05 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29724769
7.
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
Clin Sci (Lond);
131(4): 261-268, 2017 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28108631
8.
Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.
Circ Genom Precis Med;
15(2): e003489, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35133173
9.
Protective Effects of Medicinal Plant Decoctions on Macrophages in the Context of Atherosclerosis.
Nutrients;
13(1)2021 Jan 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33478034
10.
Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study.
Front Genet;
12: 728526, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34659352
11.
Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function.
Atherosclerosis;
326: 47-55, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33933263
12.
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
Atherosclerosis;
293: 49-56, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31835041
13.
PCSK9: from biology to clinical applications.
Pathology;
51(2): 177-183, 2019 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30522786
14.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
J Clin Lipidol;
12(1): 130-136, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29103916
15.
Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia.
JACC Basic Transl Sci;
4(3): 425-427, 2019 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31312765